IP Library Granted Patent US 10,048,269
Granted Patent B2
US 10,048,269 · App. 14/809,116 · Granted Aug 14, 2018

Assay methods involving dissociable nanoparticles

Inventors: Eric Stern (Jamaica Plain, MA); Aleksandar Vacic (Cambridge, MA); Alec Nathanson Flyer (Boston, MA)
Assignee: SELUX DIAGNOSTICS, INC.
G01N33/587B82Y15/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,048,269
App. No.
14/809,116
Granted
Aug 14, 2018
Kind
B2
Abstract

Among other things, the present invention provides assay methods for detecting or quantifying one or more analytes in a sample, which involve the use of dissociable nanoparticles that comprise one or more signaling agents (e.g., the nanoparticles conceal or partially conceal the signaling agents).

Claims (9)

1. A method of detecting an analyte, comprising:

(i) incubating a sample suspected of having an analyte of interest with a binding agent specific to the analyte under conditions that permit binding between the analyte and the binding agent; wherein the binding agent is associated with a nanoparticle comprising a first signaling agent and a second signaling agent; wherein the first signaling agent is a metalorganic species catalyst comprising a metal-tetraamidomacrocyclic ligand complex, and the second signaling agent is a pre-chemiluminophore;

(ii) dissociating the nanoparticle bound to the analyte, if any, to release the signaling agents such that it results in a signal change; and

(iii) determining presence or quantity of the analyte in the sample based on the signal change.

2. The method of claim 1 , wherein the nanoparticle further comprises one or more matrix-forming agents providing a matrix, wherein the signaling agents are embedded in the matrix.

3. The method of claim 1 , wherein the binding agent is selected from the group consisting of antibodies or antigen-binding fragments thereof, enzymes, oligonucleotides, DNA, RNA, PNA, or LNA, proteins, peptides, polypeptides, receptors, ligands, small molecules, aptamers, polysaccharides, plastibodies, affibodies, camelids, fibronectins, and a combination thereof.

4. The method of claim 1 , wherein the nanoparticle comprises one or more functional groups for conjugating the nanoparticle to the binding agent.

5. The method of claim 4 , wherein the functional group is linked to the outer surface via polyethylene glycol (PEG).

6. The method of claim 1 , wherein step (ii) and step (iii) are performed simultaneously in a solution.

Assignments (2)
SECURITY INTEREST Recorded Jul 1, 2024
From: SELUX DIAGNOSTICS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 068103/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2015
From: STERN, ERIC; VACIC, ALEKSANDAR; FLYER, ALEC NATHANSON
To: SELUX DIAGNOSTICS, INC.
Reel/Frame 036843/0110 →
Continuity (5)
Provisional Application 62194062 · Jul 17, 2015
Provisional Application 62142721 · Apr 3, 2015
Provisional Application 62053250 · Sep 22, 2014
Provisional Application 62029270 · Jul 25, 2014
Related Publication 20160047816A1 · Feb 18, 2016